Literature DB >> 11027928

Reporting the study populations of clinical trials. Clear transmission or static on the line?

S H Shapiro1, C Weijer, B Freedman.   

Abstract

In contrast to attempts that have been made to measure the clarity of reporting of the methods of clinical trials in journal articles, we report here an attempt to measure the accuracy of methods reporting. We focus in this article on eligibility criteria as a test case for the reporting of clinical trial methods. We examined the reporting of eligibility criteria in the protocol, methods paper (if applicable), journal article, and Clinical Alert for articles appearing in print between January 1988 and September 1994 for which a Clinical Alert had been issued. Eligibility criteria were further classified into five categories in order to examine the content of information loss, if any. On average, 82% of protocol eligibility criteria were reported in methods papers. Journal articles and Clinical Alerts fared somewhat worse: 63% of criteria were reported in journal articles, 19% in Clinical Alerts. In all three categories of medical communication, the reporting of criteria that defined the study disease tended to be complete; reporting of criteria relating to trial precision, patient safety, legal and ethical concerns, and administrative considerations, was not complete. We found that criteria for clinical trial eligibility are frequently under-reported in medical communications. Moreover, some of the criteria omitted are of considerable clinical importance. We suggest that in the design phase of clinical trials, proposed eligibility criteria be scrutinized closely. Those criteria that survive this scrutiny and that have clinical import must be reported upon fully and accurately when communicating trial results.

Entities:  

Mesh:

Year:  2000        PMID: 11027928     DOI: 10.1016/s0895-4356(00)00227-4

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  11 in total

Review 1.  Improving safety reporting from randomised trials.

Authors:  John P A Ioannidis; Joseph Lau
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  The effects of resistance training on quality of life in cancer: a systematic literature review and meta-analysis.

Authors:  Fiona Cramp; Abigail James; Jessica Lambert
Journal:  Support Care Cancer       Date:  2010-05-26       Impact factor: 3.603

3.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

4.  Neglected external validity in reports of randomized trials: the example of hip and knee osteoarthritis.

Authors:  Nizar Ahmad; Isabelle Boutron; David Moher; Isabelle Pitrou; Carine Roy; Philippe Ravaud
Journal:  Arthritis Rheum       Date:  2009-03-15

5.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

6.  Comparison of protocols and registry entries to published reports for randomised controlled trials.

Authors:  Kerry Dwan; Douglas G Altman; Lynne Cresswell; Michaela Blundell; Carrol L Gamble; Paula R Williamson
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

7.  Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study.

Authors:  Susan T Crowley; Glenn M Chertow; Joseph Vitale; Theresa O'Connor; Jane Zhang; Roland M H Schein; Devasmita Choudhury; Kevin Finkel; Anitha Vijayan; Emil Paganini; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

8.  Factors that can affect the external validity of randomised controlled trials.

Authors:  Peter M Rothwell
Journal:  PLoS Clin Trials       Date:  2006-05

9.  Declaration of transparency for each research article.

Authors:  Douglas G Altman; David Moher
Journal:  BMJ       Date:  2013-08-07

Review 10.  Clinical and economic burden of adverse drug reactions.

Authors:  Janet Sultana; Paola Cutroneo; Gianluca Trifirò
Journal:  J Pharmacol Pharmacother       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.